Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community-Acquired Infections | 14 | 2023 | 92 | 3.450 |
Why?
|
| Pneumonia | 11 | 2024 | 281 | 2.570 |
Why?
|
| Anti-Bacterial Agents | 18 | 2023 | 734 | 1.410 |
Why?
|
| Pneumonia, Bacterial | 6 | 2019 | 88 | 1.340 |
Why?
|
| Cross Infection | 7 | 2020 | 149 | 1.310 |
Why?
|
| Influenza, Human | 6 | 2022 | 192 | 1.290 |
Why?
|
| Universal Precautions | 2 | 2023 | 3 | 1.010 |
Why?
|
| Guideline Adherence | 4 | 2017 | 292 | 1.000 |
Why?
|
| Pandemics | 9 | 2024 | 616 | 1.000 |
Why?
|
| Staphylococcal Infections | 2 | 2020 | 122 | 0.900 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2021 | 62 | 0.860 |
Why?
|
| Hand Disinfection | 2 | 2014 | 15 | 0.850 |
Why?
|
| Physicians | 2 | 2020 | 440 | 0.720 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 29 | 0.680 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 411 | 0.660 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2011 | 86 | 0.660 |
Why?
|
| Survivors | 1 | 2020 | 149 | 0.650 |
Why?
|
| Staphylococcus aureus | 4 | 2022 | 169 | 0.650 |
Why?
|
| Burnout, Professional | 1 | 2020 | 125 | 0.570 |
Why?
|
| Infection Control | 5 | 2024 | 94 | 0.560 |
Why?
|
| Patient Safety | 1 | 2020 | 237 | 0.550 |
Why?
|
| Humans | 50 | 2024 | 59366 | 0.550 |
Why?
|
| Quality of Health Care | 1 | 2020 | 513 | 0.490 |
Why?
|
| Immunocompromised Host | 2 | 2013 | 100 | 0.470 |
Why?
|
| Hand Hygiene | 1 | 2014 | 7 | 0.470 |
Why?
|
| Disease Outbreaks | 3 | 2024 | 102 | 0.460 |
Why?
|
| Retrospective Studies | 16 | 2024 | 6069 | 0.460 |
Why?
|
| Caliciviridae Infections | 1 | 2013 | 4 | 0.420 |
Why?
|
| Norovirus | 1 | 2013 | 6 | 0.420 |
Why?
|
| Gastroenteritis | 1 | 2013 | 12 | 0.420 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 205 | 0.410 |
Why?
|
| Length of Stay | 4 | 2023 | 776 | 0.400 |
Why?
|
| United States | 16 | 2024 | 7426 | 0.400 |
Why?
|
| Hospitalization | 9 | 2024 | 1290 | 0.370 |
Why?
|
| Seasons | 2 | 2020 | 123 | 0.370 |
Why?
|
| Myocarditis | 1 | 2011 | 60 | 0.340 |
Why?
|
| Behavior | 1 | 2010 | 36 | 0.330 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2010 | 27 | 0.330 |
Why?
|
| Hospital Mortality | 3 | 2021 | 841 | 0.330 |
Why?
|
| Respiratory Insufficiency | 2 | 2019 | 148 | 0.320 |
Why?
|
| Motivation | 1 | 2012 | 274 | 0.320 |
Why?
|
| Anti-Infective Agents | 2 | 2021 | 143 | 0.310 |
Why?
|
| Surgical Wound Infection | 1 | 2010 | 110 | 0.310 |
Why?
|
| Adult | 14 | 2024 | 15679 | 0.300 |
Why?
|
| Methicillin Resistance | 1 | 2008 | 21 | 0.300 |
Why?
|
| Clostridium Infections | 2 | 2022 | 45 | 0.290 |
Why?
|
| Ethanol | 1 | 2010 | 306 | 0.270 |
Why?
|
| Epidemiologists | 1 | 2024 | 1 | 0.230 |
Why?
|
| Personal Protective Equipment | 1 | 2024 | 29 | 0.220 |
Why?
|
| Resuscitation Orders | 1 | 2024 | 48 | 0.210 |
Why?
|
| Data Collection | 1 | 2024 | 371 | 0.200 |
Why?
|
| Aged | 12 | 2024 | 13405 | 0.190 |
Why?
|
| Treatment Outcome | 8 | 2017 | 5281 | 0.190 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 68 | 0.190 |
Why?
|
| Anaphylaxis | 1 | 2022 | 40 | 0.190 |
Why?
|
| Health Facilities | 1 | 2021 | 41 | 0.180 |
Why?
|
| Federal Government | 1 | 2021 | 19 | 0.180 |
Why?
|
| Mandatory Programs | 1 | 2021 | 17 | 0.180 |
Why?
|
| Legionnaires' Disease | 1 | 2020 | 8 | 0.180 |
Why?
|
| Masks | 1 | 2021 | 20 | 0.180 |
Why?
|
| Blood Culture | 1 | 2020 | 11 | 0.180 |
Why?
|
| Local Government | 1 | 2021 | 12 | 0.180 |
Why?
|
| State Government | 1 | 2021 | 29 | 0.180 |
Why?
|
| Drug Resistance, Microbial | 1 | 2020 | 47 | 0.180 |
Why?
|
| Coinfection | 1 | 2021 | 44 | 0.180 |
Why?
|
| Fluoroquinolones | 2 | 2022 | 31 | 0.180 |
Why?
|
| Microbiological Techniques | 1 | 2020 | 5 | 0.170 |
Why?
|
| Health Personnel | 1 | 2024 | 342 | 0.170 |
Why?
|
| Antimicrobial Stewardship | 1 | 2020 | 16 | 0.170 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2020 | 27 | 0.170 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 28 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 42 | 0.170 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2022 | 83 | 0.170 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2010 | 49 | 0.170 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 5119 | 0.170 |
Why?
|
| Viruses | 1 | 2020 | 78 | 0.170 |
Why?
|
| Communicable Diseases | 1 | 2020 | 85 | 0.160 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 131 | 0.160 |
Why?
|
| Superinfection | 2 | 2010 | 10 | 0.160 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 306 | 0.160 |
Why?
|
| Calcitonin | 1 | 2017 | 17 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 192 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 705 | 0.130 |
Why?
|
| Alcoholism | 1 | 2019 | 309 | 0.130 |
Why?
|
| Female | 12 | 2020 | 30719 | 0.130 |
Why?
|
| Middle Aged | 11 | 2020 | 16310 | 0.120 |
Why?
|
| Risk Assessment | 4 | 2022 | 1925 | 0.120 |
Why?
|
| Male | 12 | 2020 | 27742 | 0.120 |
Why?
|
| Hygiene | 1 | 2014 | 11 | 0.120 |
Why?
|
| Sepsis | 2 | 2019 | 272 | 0.120 |
Why?
|
| Risk Factors | 3 | 2020 | 4986 | 0.110 |
Why?
|
| Antiviral Agents | 2 | 2022 | 313 | 0.110 |
Why?
|
| Drug Utilization | 1 | 2015 | 208 | 0.110 |
Why?
|
| Health Policy | 2 | 2024 | 177 | 0.100 |
Why?
|
| Age Distribution | 2 | 2010 | 250 | 0.100 |
Why?
|
| Lecithin Cholesterol Acyltransferase Deficiency | 1 | 2011 | 2 | 0.100 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2011 | 6 | 0.090 |
Why?
|
| Homozygote | 1 | 2011 | 114 | 0.090 |
Why?
|
| Peer Group | 1 | 2012 | 95 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 657 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2011 | 172 | 0.090 |
Why?
|
| Gentamicins | 1 | 2010 | 23 | 0.090 |
Why?
|
| Immune Sera | 1 | 2010 | 34 | 0.090 |
Why?
|
| Sterilization | 1 | 2010 | 15 | 0.080 |
Why?
|
| Catheter-Related Infections | 1 | 2010 | 41 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 176 | 0.080 |
Why?
|
| Catheters, Indwelling | 1 | 2010 | 67 | 0.080 |
Why?
|
| Surgical Instruments | 1 | 2010 | 41 | 0.080 |
Why?
|
| Prognosis | 2 | 2019 | 1597 | 0.080 |
Why?
|
| Operating Rooms | 1 | 2010 | 55 | 0.080 |
Why?
|
| New England | 1 | 2010 | 267 | 0.080 |
Why?
|
| Myocardium | 1 | 2011 | 264 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2023 | 355 | 0.080 |
Why?
|
| Trauma Centers | 1 | 2010 | 114 | 0.080 |
Why?
|
| Heart | 1 | 2011 | 274 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2010 | 189 | 0.080 |
Why?
|
| Surgical Procedures, Operative | 1 | 2010 | 137 | 0.080 |
Why?
|
| Methicillin | 1 | 2008 | 4 | 0.070 |
Why?
|
| Orthomyxoviridae | 1 | 2008 | 26 | 0.070 |
Why?
|
| Bacteriological Techniques | 1 | 2008 | 28 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 204 | 0.070 |
Why?
|
| Echocardiography | 1 | 2011 | 457 | 0.070 |
Why?
|
| Culture Media | 1 | 2008 | 77 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 250 | 0.070 |
Why?
|
| Influenza Vaccines | 1 | 2008 | 91 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2010 | 717 | 0.070 |
Why?
|
| Young Adult | 2 | 2014 | 4273 | 0.060 |
Why?
|
| Hospitals | 2 | 2020 | 377 | 0.060 |
Why?
|
| Strategic Stockpile | 1 | 2024 | 1 | 0.060 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2024 | 21 | 0.060 |
Why?
|
| Time Factors | 2 | 2010 | 3615 | 0.060 |
Why?
|
| Adolescent | 2 | 2020 | 5835 | 0.060 |
Why?
|
| Disaster Planning | 1 | 2024 | 48 | 0.060 |
Why?
|
| Information Dissemination | 1 | 2024 | 111 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2022 | 16 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 2380 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 337 | 0.050 |
Why?
|
| Macrolides | 1 | 2022 | 37 | 0.050 |
Why?
|
| Oseltamivir | 1 | 2022 | 34 | 0.050 |
Why?
|
| Legionella pneumophila | 1 | 2020 | 10 | 0.050 |
Why?
|
| Comorbidity | 1 | 2024 | 1078 | 0.040 |
Why?
|
| Blood-Borne Pathogens | 1 | 2020 | 12 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2020 | 37 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2020 | 63 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 220 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2015 | 554 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2020 | 61 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2020 | 171 | 0.040 |
Why?
|
| Communication | 1 | 2024 | 545 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 451 | 0.040 |
Why?
|
| Pneumonia, Aspiration | 1 | 2019 | 17 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 495 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2015 | 2375 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 166 | 0.040 |
Why?
|
| Inpatients | 1 | 2020 | 291 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1027 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 1091 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 814 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 403 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 1479 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1465 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 61 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 902 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 725 | 0.030 |
Why?
|
| Nursing Homes | 1 | 2020 | 661 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 119 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1189 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 2053 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1119 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 1306 | 0.020 |
Why?
|
| Corneal Opacity | 1 | 2011 | 4 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2011 | 21 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 39 | 0.020 |
Why?
|
| Proteinuria | 1 | 2011 | 38 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 35 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 188 | 0.020 |
Why?
|
| Endocarditis, Bacterial | 1 | 2010 | 31 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 252 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 394 | 0.020 |
Why?
|
| Heparin | 1 | 2010 | 111 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 409 | 0.020 |
Why?
|
| Shock, Septic | 1 | 2010 | 86 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 329 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 1553 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 470 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2010 | 303 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 244 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2010 | 480 | 0.020 |
Why?
|
| Vaccination | 1 | 2008 | 337 | 0.020 |
Why?
|
| Massachusetts | 1 | 2010 | 2019 | 0.010 |
Why?
|
| Infant | 1 | 2008 | 1491 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 2338 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 19649 | 0.010 |
Why?
|
| Pregnancy | 1 | 2008 | 2213 | 0.010 |
Why?
|